Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As2O3) on myeloma cells
- 20 February 2001
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 25 (3), 227-235
- https://doi.org/10.1016/s0145-2126(00)00105-3
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- CD38/CD31, a Receptor/Ligand System Ruling Adhesion and Signaling in Human LeukocytesPublished by S. Karger AG ,2000
- Human myeloma cells express the CD38 ligand CD31British Journal of Haematology, 1999
- Arsenic — New Life for an Old PotionNew England Journal of Medicine, 1998
- Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic TrioxideNew England Journal of Medicine, 1998
- Differentiation, differentiation/gene therapy and cancerPharmacology & Therapeutics, 1997
- Lymphocyte Adhesion to EndotheliumCritical Reviews in Immunology, 1995
- Human CD38: a glycoprotein in search of a functionImmunology Today, 1994
- The high lysability by lak cells of colon‐carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM‐1, LFA‐3, NCA and a less‐differentiated phenotypeInternational Journal of Cancer, 1991
- Human Myeloma Cell Line Carrying a Philadelphia ChromosomeScience, 1982
- Action of Iron, Cod-liver Oil, and Arsenic on the Globular Richness of the BloodThe American Journal of the Medical Sciences, 1878